Quantum BioPharma Announces Corporate Updates Including Debt Settlement and Advisor Changes

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91), a biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders, has announced several significant corporate actions that demonstrate strategic financial management and commitment to advancing its clinical programs. On August 12, 2025, the company's board approved the settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share, effectively converting debt into equity and strengthening the company's balance sheet.

Three days later, on August 15, 2025, the board granted 800 restricted share units each to clinical advisors Peter Stys and Jack Antel under the company's equity incentive plan. These RSUs have vesting conditions specifically tied to regulatory milestones for Quantum BioPharma's Lucid MS program, aligning advisor compensation with the successful development of this promising treatment candidate. The creditor shares and RSUs are subject to a four-month-plus-one-day statutory hold period under CSE policy and are not registered under the U.S. Securities Act, ensuring compliance with regulatory requirements.

The company also announced that effective August 15, 2025, Kevin Malone is no longer serving as an advisor to the board following the termination of his agreement. This change in advisory composition comes as Quantum BioPharma continues to focus on its core development programs, particularly through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is advancing the research and development of Lucid-MS. This patented new chemical entity has demonstrated the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models, representing a potentially transformative approach to treating neurodegenerative conditions.

Quantum BioPharma maintains additional value through its ownership stake in Celly Nutrition Corp., which commercializes the OTC version of UNBUZZD™, with Quantum retaining 25.71% ownership as of June 30, 2024, and receiving royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% rights to develop similar products for pharmaceutical and medical uses, providing multiple pathways for value creation. Additional strategic investments are managed through FSD Strategic Investments Inc., representing loans secured by residential or commercial property. Investors can access the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.